Related references
Note: Only part of the references are listed.High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients
NiJiati AiErken et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2017)
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility
Andrea Ravelli et al.
TUMOR BIOLOGY (2017)
Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome
Rhiannon K. Beckers et al.
HISTOPATHOLOGY (2016)
Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer
M. Miyan et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review
Sasha E. Stanton et al.
JAMA ONCOLOGY (2016)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy n stroke
Sheetal Bodhankar et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2014)
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
S. Muenst et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
St. Gallen 2013: Brief Preliminary Summary of the Consensus Discussion
Nadia Herbeck et al.
BREAST CARE (2013)
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
Makiko Ono et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer
Rin Yamaguchi et al.
HUMAN PATHOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes
Fangfang Liu et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Complex roles of Stat1 in regulating gene expression
CV Ramana et al.
ONCOGENE (2000)
Share Paper
